Akili announces positive results from shionogi's phase 3 clinical trial of localized version of akili's endeavorrx® for pediatric adhd patients in japan

Boston--(business wire)--akili, inc. (nasdaq: akli), a leading digital medicine company, today announced that its japanese partner shionogi & co. ltd has submitted akili's digital therapeutic sdt-001 for marketing approval with the ministry of health, labor, and welfare. sdt-001 is the japanese, localized version of akili's akl-t01 (marketed as endeavorrx® in the united states), which has previously been authorized by the u.s. food and drug administration (fda) as the world's first prescrip.
AKLI Ratings Summary
AKLI Quant Ranking